CMS has announced its plans to evaluate a new value-based payment model for prescription drugs covered under the Part B program. This is yet another move by the federal body to ensure quality care for Medicare enrollees.
CMS has announced its plans to evaluate a new value-based payment model for prescription drugs covered under the Part B program. This is yet another move by the federal body to ensure quality care for Medicare enrollees.
Medicare Part B covers prescription drugs that are administered in a physician’s office or hospital outpatient department, such as cancer medications, injectables like antibiotics, or eye care treatments. These drugs usually fall into 1 of 3 categories:
The new model being proposed will support clinical decisions as providers choose the drug that is right for their patients, the emphasis being on choosing the most effective or high-value drugs, and providing incentives/rewards for improved outcomes. Beginning late 2016, the proposed model will test whether changing the add-on payment to the average sales price from 6% to 2.5% plus a flat fee payment of $16.80 per drug per day changes prescribing incentives.
“First and foremost, our job is to get beneficiaries the medications they need. These proposals would allow us to test different ways to help Medicare beneficiaries get the right medications and right care while supporting physicians in the process,” said Andy Slavitt, acting administrator for CMS, in a statement. “This is consistent with our focus on testing value-based care models like we have been doing with physicians and hospitals in ACOs. Models like this one can help doctors and other clinicians do what they do best: choose the medicine and treatment that keeps their patients healthy.”
CMS has proposed 6 alternative approaches on pricing strategies for Part B drugs that emphasize value-based purchasing. These include:
CMS plans to test the model for a period of 5 years, with the incentive and value-based purchasing tests fully operational during the last 3 years to monitor changes and gather enough evidence. Success of the model will be gauged based on net reductions in Medicare spending without compromising on coverage or benefits, while maintaining or improving patient care. CMS will launch a concurrent real-time claims monitoring program to track utilization, spending, and prescribing patterns as well as changes in site of service delivery, mortality, hospital admissions, and several other high-level claims-based measures.
“These models would test how to improve Medicare beneficiaries’ care by aligning incentives to reward value and the most successful patient outcomes,” said Patrick Conway, MD, MSC, deputy administrator for Innovation and Quality and chief medical officer of CMS, in a statement. “The choice of medications for beneficiaries should be driven by the best available evidence, the unique needs of the patient, and what best promotes high quality care.”
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More